Skip to main content

Table 5 Final model resulting from multinomial logistic regression for factors associated with unfavorable outcomes in new cases of drug-resistant pulmonary tuberculosis, Brazil, 2013 and 2014. (980 cases)

From: Brazilian cohort study of risk factors associated with unsuccessful outcomes of drug resistant tuberculosis

  Lost to follow-up Failure Death
  Adjusted OR (CI95%) p value* Adjusted OR (CI95%) p value* Adjusted OR (CI95%) p value*
Block I          
Race/color
White 1.0    1.0    1.0   
Brown/Black1 1.1 (0.73–1.58) 0.72 1.1 (0.62–1.90) 0.76 1.7 (1.08–2.77) 0.02
Asian/Indigenous 0.8 (0.08–6.77) 0.80    0.99    0.99
Age group (years)
15–59 1.0    1.0    1.0   
60 or more 0.4 (0.18–1.09) 0.08 1.1 (0.44–2.82) 0.81 3.4 (1.90–6.03)  < 0.01
Education (years)
0 to 7 1.8 (1.13–2.66) 0.01 0.9 (0.50–1.59) 0.69 1.9 (1.09–3.19) 0.02
8 or more 1.0    1.0    1.0   
Missing 1.8 (0.89–3.62) 0.10 0.6 (0.17–1.90) 0.36 2.8 (1.27–6.02) 0.01
HIV
Positive 1.0 (0.57–1.85) 0.94 1.0 (0.39–2.52) 0.99 2.7 (1.45–4.83)  < 0.01
Negative 1.0    1.0    1.0   
Missing 1.2 (0.66–2.02) 0.61 0.8 (0.36–1.97) 0.70 1.5 (0.79–2.76) 0.22
Use of illicit drugs
Yes 2.5 (1.57–3.82)  < 0.01 0.9 (0.41–2.06) 0.84 1.3 (0.73–2.38) 0.37
No/don't know 1.0    1.0    1.0   
Prison population
Yes 1.3 (0.64–2.65) 0.48 0.5 (0.06–3.85) 0.48 0.1 (0.02–1.01) 0.05
No/don't know 1.0    1.0    1.0   
Block II          
Bilateral disease
Yes 1.2 (0.89–1.71) 0.43 2.0 (1.09–3.62) 0.03 1.9 (1.20–3.08) 0.01
No 1.0    1.0    1.0   
Resistance type          
Primary 1.0    1.0    1.0   
Acquired 1.4 (0.87–2.17) 0.17 1.3 (0.66–2.50) 0.47 1.8 (1.02–3.31) 0.04
Initial resistance pattern
MDR/RR 1.0    1.0    1.0   
XDR 0.7 (0.07–6.25) 0.73 1.5 (0.22–9.69) 0.70 7.3 (1.97–27.09)  < 0.01
Injectable drug treatment
Only used Am 1.0    1.0    1.0   
Only used S 0.9 (0.58–1.38) 0.61 1.0 (0.51–1.90) 0.97 0.8 (0.52–1.38) 0.50
Only use Cm 1.4 (0.59–3.24) 0.46 1.7 (0.51–5.55) 0.40 0.8 (0.25–2.61) 0.73
Used more than one injectable or did not use 0.9 (0.36–2.13) 0.76 2.8 (1.05–7.69) 0.04 1.5 (0.60–3.61) 0.40
Block III          
Resides in different municipality than treatment
Yes 0.7 (0.46–0.99) 0.04 1.7 (0.97–2.92) 0.07 0.8 (0.54–1.31) 0.45
No 1.0    1.0    1.0   
Reported unfavorable clinical evaluation
Yes 3.1 (2.02–4.86)  < 0.01 18.0 (10.18–31.90)  < 0.01 3.3 (2.02–5.44)  < 0.01
No 1.0    1.0    1.0   
Changed regimen type
Yes 0.6 (0.30–1.07) 0.08 0.7 (0.35–1.57) 0.43 0.4 (0.17–0.76) 0.01
No 1.0    1.0    1.0   
Had adverse reaction
No adverse reaction records 1.0    1.0    1.0   
Only minor adverse reactions 0.5 (0.25–0.83) 0.01 1.3 (0.66–2.52) 0.45 0.6 (0.33–1.23) 0.18
At least one major adverse reaction 0.6 (0.24–1.32) 0.18 0.3 (0.06–1.21) 0.09 0.8 (0.33–1.85) 0.58
  1. IBlack = combines black and brown
  2. OR odds ratio, CI confidence interval, MDR multidrug resistant, RR resistant to rifampicin diagnosed by GeneXpert MTB/RIF® (RR), XDR extensively resistant, Am amikacin, S streptomycin, Cm capreomycin
  3. *Significance level = 0.05
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us